Protein kinase A (PKA)-induced estrogen receptor alpha (ERa) phosphorylation at serine residue 305 (ERaS305-P) can induce tamoxifen (TAM) resistance in breast cancer. How this phospho-modification affects ERa specificity and translates into TAM resistance is unclear. Here, we show that S305-P modification of ERa reprograms the receptor, redirecting it to new transcriptional start sites, thus modulating the transcriptome. By altering the chromatin-binding pattern, Ser305 phosphorylation of ERa translates into a 26-gene expression classifier that identifies breast cancer patients with a poor disease outcome after TAM treatment. MYC-target genes and networks were significantly enriched in this gene classifier that includes a number of selective targets for ERaS305-P. The enhanced expression of MYC increased cell proliferation in the presence of TAM. We demonstrate that activation of the PKA signaling pathway alters the transcriptome by redirecting ERa to new transcriptional start sites, resulting in altered transcription and TAM resistance.
INTRODUCTION
Breast cancer is the most frequently diagnosed malignancy among women, with annually around 1.4 million new diagnoses worldwide. Although treatment has strongly improved with the development of adjuvant systemic therapies, still about half a million patients die of the consequences of breast cancer every year. 1 The choice of adjuvant treatment is largely based on the pathological subtype of the breast tumor, which can be classified by morphological, molecular and immunohistochemical markers. These subtypes correspond to distinct transcriptional repertoires, which translate in a different aggressiveness and metastatic potential. 2 Seventy-five percent of all breast tumors are luminal and proliferate dependent on the activity the estrogen receptor a (ERa). Inhibition of ERa by endocrine therapy is therefore a major treatment modality of these tumors. Endocrine therapy can be subdivided into two treatment modalities; aromatase inhibitors that block synthesis of the hormone estrogen and anti-estrogens. Anti-estrogens (including tamoxifen, TAM) compete with natural estrogens by occupying the hormone-binding site of ERa and either arresting it in the inactive state 3 or inducing degradation of the receptor. 4 However, patients can acquire resistance to either type of endocrine therapy. About 25% of the TAM-treated tumors are resistant to this anti-estrogen, even though the tumor continues expressing ERa. 5 Consequently, patients unresponsive to TAM may still respond to other anti-estrogens such as fulvestrant or to aromatase inhibitors. 4 A major step in treatment success would be achieved when responses to endocrine treatment could be predicted on an individualized basis. Detection of ERaS305-P in patient tissues has provided a means of selecting a group of patients resistant to TAM before the onset of treatment. [5] [6] [7] However, not all TAM-resistant patients can be identified by this staining, and alternative resistance-inducing mechanisms are likely to have a role in the remaining patient group. Indeed, several causes and contributing factors for inducing TAM resistance have been described in breast cancer patients or cell models, including upregulation of growth factor receptors (like EGFR (epidermal growth factor receptor), 8, 9 IGFR (insulin-like growth factor receptor) and HER2 (human epidermal growth factor receptor 2) 10, 11 ), activation of kinases (such as AKT, 12 MAPK, 13, 14 protein kinase A (PKA) in combination with PAK1 6, 15, 16 ), and the resulting phosphorylation status of ERa. [17] [18] [19] [20] The effects of PKA-induced phosphorylation of ERa at Serine residue 305 (ERaS305-P) in the region between the ligand-binding domain and the DNA-binding domain are understood in molecular detail. Phosphorylation at Ser305 results in a conformational arrest when exposed to TAM, 17 which affects recruitment of coregulators. 21 Consequently, TAM acts as an agonist of ERa instead of an antagonist, now inducing cell growth of breast cancer cell lines. 17, 22 An antibody detecting ERaS305-P in tumor sections was successful in identifying breast cancer patients with a poor outcome after TAM treatment, 6, 5, 7 translating observations in tissue culture into clinical patient responses.
As the ER is a nuclear receptor, and its phosphorylation affects recruitment of coregulators, the chromatin-binding landscape of the receptor and corresponding influence on the transcriptome may change following this modification. Several kinase pathways including PKA link to TAM resistance. 17, 22, 23 Several classical targets for ERa were differentially regulated including trefoil factor 1 (TFF1). 22 PKA-activation does not only phosphorylate ERa, but has many targets, including coregulators of the receptor. [24] [25] [26] The phosphostatus of coregulators can also affect ERa function, thereby indirectly affecting the ERa cistrome and transcriptome. 26, 27 Other PKA targets may even bypass the receptor and change the transcriptome independently. As kinase activity can alter the chromatin-interaction landscape of ERa, 28 deciphering a direct connection between ERaS305-P modification and direct targets is essential for understanding TAM resistance. Here, we aim to define the direct target genes of the modified ERaS305-P and test whether that yields predictors for TAM resistance. We determined the resulting transcriptome and performed further bioinformatic analyses to determine a predicting gene signature in patient material. This signature includes unique ERaS305-P induced pathways that explain PKA-related TAM resistance.
RESULTS

ERaS305 phosphorylation by PKA
To study PKA-induced TAM resistance, we used two well-defined and intensely studied breast cancer cell lines MCF7 and MDA-MB-134. Both MCF7 and MDA-MB-134 express ERa and require estrogens for growth, which is inhibited by TAM. 17, 29 In MCF7 cells, we activated the PKA pathway by forskolin 30 (Figure 1a top) and isolated RNA for microarray and qPCR analyses after 4 h of TAM exposure to probe early transcriptional responses of ERaS305 phosphorylation. Forskolin treatment induces phosphorylation of ERaS305 as detected by a specific antibody (Figure 1b top) . Although we chemically activated the PKA pathway in MCF7 cells, we decided to confirm results by genetically activating this pathway in MDA-MB-134 cells. Here, PKA was activated by silencing the inhibitory subunit of PKA, PKA-RIa (Figure 1a bottom) , 31 which is also observed in TAMresistant patients. 17 When PKA-RIa is silenced, PKA is activated yielding phosphorylation of ERaS305. 17 Silencing PKA-RIa was confirmed by western blot analysis (Figure 1b bottom) . In addition, increased phosphorylation of PKA substrate CREB confirms that PKA is activated in both cell lines (Figure 1b) , yielding an elevated ERaS305-P signal. When both methods of PKA-activation are exchanged between the two cell line models, this still resulted in ERaS305 phosphorylation (Supplementary Figure S1) .
A gene signature for TAM resistance after PKA-activation We analyzed the effects of PKA-induced ERaS305 phosphorylation on the transcriptome by expression microarray analysis. Under conditions corresponding to the experiments above (Figure 1 ), cells were deprived of hormones for 3 days and subsequently treated with TAM, after which the influence of PKA-activation was assessed in both cell lines (Figure 2) . PKA was chemically activated in MCF7 cells and genetically in MDA-MB-134 cells. Gene expression distribution is illustrated by the log-ratio, for PKAactivated versus non-activated cells, over intensity (RI) dot plots (Figure 2a) . In MCF7 cells, we identified 152 upregulated and 108 downregulated genes following PKA-activation (260 in total). In MDA-MB-134, we find 385 up-and 437 downregulated genes (822 in total) (Supplementary Tables S1 and S2). In these gene expression profiles, 59 up-and 41 downregulated genes overlap between MCF7 and MDA-MB-134 (Figure 2b and Supplementary  Tables S3 and S4 ). By focusing on the overlap of 100 differentially regulated genes, we eliminated cell line or treatment-specific effects. Among the upregulated hits are two classical targets for estradiol-stimulated ERa: TFF1 and XBP1, the latter of which is in the top 5 of differentially regulated genes. The top 10 up-and downregulated hits for MCF7 and MDA-MB-134 cells are indicated (Figure 2c) , and a subset was tested and confirmed by qPCR ( Figure 2d ). Next, we tested the 100 differentially regulated genes that are shared between the two cell lines and conditions (59 up, 41 down) as a classifier to identify ERa-positive breast cancer patients responding poorly to TAM treatment, using a publically available data set. 32 The gene classifier was found to significantly correlate with poor outcome after TAM treatment (P ¼ 0.019; hazard ratio ¼ 2.5) (Figure 2e top) . This classifier was validated in an independent patient series, 33 again identifying the patients with a poor outcome after TAM treatment (P ¼ 0.045; hazard ratio ¼ 1.97, Figure 2e bottom).
S305-P modification of ERa targets the receptor to promoters PKA activity results in the phosphorylation of many targets, including ERa. ERa itself has two target sites for PKA, Serine 236 34 and Serine 305, the latter of which is predominant and correlates to TAM resistance. 17 To determine the effects of ERaS305 phosphorylation on gene transcription and chromatin deposition, we analyzed the chromatin-binding landscape of ERaS305-P by means of ChIP-seq with a specific monoclonal antibody. 5 To this purpose, cells were cross-linked, chromatin fragmented and ERaS305-P immuno-precipitated. The co-isolated chromatin fragments were amplified, sequenced and mapped against the human genome reference (Figure 3a) . 35 MCF7 cells were hormone deprived for 3 days and stimulated with forskolin. As transcriptional alterations were observed 4 h after TAM treatment, the chromatin-interaction patterns of ERaS305-P were studied at an earlier time point as DNA binding precedes transcription. ERaS305-P-binding patterns were compared with chromatin interactions of total ERa from asynchronously proliferating MCF7 cells 36 to determine the shared events and unique binding sites for the phosphorylated receptor. ERaS305-P shows 3327 binding events, of which 912 overlap with total ERa (Figure 3c ). The unique subsets of binding patterns were not due to differences in peak-calling thresholds, as shown in the raw heatmap distributions (Figure 3d ). These data imply that S305-phosphorylated ERa shares only a subset of the conventional ERa-binding sites, but also has its own specific targets sites. Examples of shared and unique sites are shown in Figure 3b . Only a subset of the ERaS305-P-binding sites as induced by PKA stimulation are shared with EGF-induced ERa chromatin interactions (Supplementary Figure S2) . 28 These data suggest that distinct ERa-chromatin-interaction patterns are induced through different kinase pathways. When the ERaS305-P peaks were annotated, a striking enrichment for ERaS305-P was observed for 0 -UTRs and 5 0 -UTRs, whereas total ERa generally prefers distal enhancers (Figure 3e), as was described before. 37, 38 This enrichment on promoter regions is not only observed for the shared interaction sites, but also for unique ERaS305-P peaks. Interestingly, we observed distinct enriched DNA motifs for ERaS305-P as compared with total ERa, implying an active retargeting of the receptor to uncommon sites ( Figure 3f ). The top three enriched motifs underlying ERaS305-P-binding events were AHR, EGR3 and E2F1. The biological relevance of these transcription factors in TAM resistance was assessed in a cell proliferation assay, which demonstrated that knockdown of AHR, EGR3 and E2F1 can all overcome the growth advantage of PKA-activated MCF7 cells under TAM conditions (Supplementary Figure S3) . Concluding, modification of ERa at Ser305 not only affects ERa conformation, 17 but also chromatin-binding sites, transcription and cellular responses.
Interconnection of genes in the classifier
To understand how phosphorylation of ERaS305 drives differential gene expression, resulting in TAM unresponsiveness of breast tumors, we decided to define the functional networks that are differentially (in)activated because of the modification of ERa. An ingenuity pathway analysis of the differentially regulated genes in both conditions was performed, which identifies functional connections from a gene list using literature data. Within the top pathways listed in Figure 4a , classical ERa targets (TFF1, XBP1, CAV1) as well as interacting partners of ERa for non-classical gene transactivation, such as AP-1 and NFkB (Supplementary Figure S4) were found, illustrating expected ERa-mediated gene expression rather than only PKA-activation. Nonetheless, a pathway analysis comparison between ERaS305-P and estradiol stimulation of ERa results in enrichment of distinct molecular pathways (Supplementary Table S5 and Supplementary Figure S5) .
PKA-activation can induce cell growth in TAM-treated breast cancer cells. 22, 17 We therefore focused on the third network, which links genes in the classifier to cell growth and proliferation. This network includes MYC as a central player (Figure 4b) . MYC is not a direct hit in our microarray analysis as it was enriched just below the threshold (1.49 Â ) in MCF7 cells. We validated elevated MYC expression in MCF7 cells following forskolin and TAM stimulation by a more quantitative method: qPCR (Figure 4c ). PKA-activation combined with TAM treatment upregulates MYC expression 1.65-fold, directly coupling ERaS305 phosphorylation to expression of a well-known oncogene involved in TAM resistance. 39, 40 Of note, Myc upregulation is already observed after PKA treatment alone, and no additional treatment with TAM is required.
Integration of ERaS305-P chromatin binding with gene expression signatures Selective ERaS305-P interactions with chromatin should translate into transcriptional differences. To assess these, we integrated the ChIP-seq data with the expression data obtained from the microarray studies. This allowed us to extract the direct targets of ERaS305-P from the bulk of genes that are differentially regulated because of overall PKA-activation. Among the 100 hits from our classifier, we defined the genes that had a chromatinbinding peak for ERaS305-P within a 20 kb region from the transcription start site, which indicates direct transcriptional regulation by the receptor. 41 This identified 26 genes as direct targets of ERaS305-P: 14 of these genes were upregulated and 12 downregulated (Figure 5a ). Of these direct ERaS305-P targets, nine are distinct from estradiol-stimulated, total ERa, implying that they are specific for the phosphorylated form. Utilized as a classifier in Examples of chromatin interaction to two gene areas for total ERa (green) and S305-phosphorylated ERa (blue). Retinoic acid receptor alpha (RARA) has an ERa-binding site within a 20-k nucleotide region of the transcription start, to which ERaS305-P also binds. S100P shows binding for both total and phosphorylated ERa, but ERaS305-P prefers the promoter, whereas total ERa binds to a distal enhancer. Arrows denote binding peaks. (c) Venn diagram, showing the overlap of ERaS305-P (blue) chromatin-binding events versus total ERa (green). Number of shared or unique peaks is indicated. Called peaks were interrogated for overlap and intersected using Galaxy (http://main.g2.bx.psu.edu/). (d) Heat-map visualization of the shared and unique peaks for ERaS305-P (blue) and E2-ERa (green). Top: Shown are all peak regions, which were vertically aligned and centered on the binding site (arrowhead) with a 5-kb window. Bottom: the signals were quantified and visualized in a 2D line graph, showing the average tag count for ERaS305-P (blue) and total ERa (green) at the shared and unique regions with a 2.5-kb window. (e) Genomic distribution of overall ERaS305-P binding (left), total ERa (right) and sites shared between the two (middle). The genomic distributions of binding sites were analyzed using the cis-regulatory element annotation system (CEAS). 57 The genes closest to the binding site on both strands were analyzed. If the binding region is within a gene, CEAS software indicates whether it is in a 5 0 -UTR, a 3 0 -UTR, a coding exon, or an intron. Promoter is defined as 1 kb upstream from RefSeq 5 0 start. If a binding site is 41 kb away from the RefSeq transcription start site, it is considered distal intergenic. ERaS305-P shows preference for promoter sites. (f ) Motif analysis of binding sites for ERaS305-P (blue) and total, estradiol-stimulated ERa (green) show a difference in motif preference. To identify motifs, SeqPos was used. 58 SeqPos uses the distances from motif positions to the peak summits (center of the regions) to find the most enriched motifs near peak summits, using TRANSFAC. 33 data set, the number of patients became too small for a reliable analysis.
Next, we compared the direct ERaS305-P targets with the nonphosphorylated ERa with respect to TAM-agonistic response, as measured by qPCR. For the non-S305-P target genes, the PKAstimulatory effects were identical for TAM and vehicle-treated cells implying no TAM-agonism at these genes (Figure 5c ). But for the majority of the tested genes with a proximal ERaS305-P-binding site, additional transcriptional activity was observed when TAM was combined with PKA treatment, suggesting an agonistic response in addition to the effects of PKA stimulation alone (Figure 5c ).
We then analyzed the new classifier for biological relevance. Seven of the 26 direct targets are functionally connected with MYC, implying that ERaS305-P directly affects the MYC pathway (Figure 5d ), rather than acting on Myc alone. As MYC was upregulated in the PKA-activated, TAM-treated MCF7 cells, we explored whether MYC is a direct target of ERaS305-P. To this end, the proximity of the Myc locus was analyzed for ERaS305-P peaks. We observed a chromatin-interaction peak at a distal enhancer that has recently been identified, 43 and a second peak at the promoter region of MYC (Figure 5e , arrows denote the peaks). These and other ERaS305-P/chromatin-interaction sites were independently verified by qPCR analysis (Supplementary Figure  S6) . Taken together, we show by ChIP-seq, microarray and qPCR that S305-phosphorylated ERa has a direct role in MYC transcriptional regulation. Myc upregulation will subsequently affect cell proliferation in response to TAM.
To directly assess the influence of MYC on MCF7 cells proliferation, and the influence of TAM treatment thereon, MYC was transiently overexpressed in MCF7 cells (Figure 5f ; protein overexpression confirmed in Figure 5g ). This resulted in a significant increase in cell proliferation both in absence and presence of TAM, linking the enhanced expression of MYC with cell growth even in presence of this anti-estrogen and thus inducing resistance.
DISCUSSION
Activation of kinase pathways is one of the hallmarks of tumor formation. Most breast cancers are critically dependent on ERa and this nuclear hormone receptor can be modified by a series of kinases, including PKA. [12] [13] [14] [15] [16] [17] PKA phosphorylates ERa at position 305, inducing a conformational arrest of the receptor upon TAM exposure. 17 This eventually results in TAM resistance and cell proliferation in response to TAM exposure. 17, 22 However, the exact mechanism of TAM resistance remains unknown and this is studied here. We show that S305-P modification has a marked effect on the accurate positioning of ERa on transcriptional start sites. This is highly surprising and, in more general terms, suggests that post-translational modifications can have major effects on chromatin binding of transcription factors and thus the transcriptome. In fact, this couples extracellular signaling (in our case by PKA-activation) to alterations in transcriptional output by a retargeting of the transcription factor to alternative binding regions.
The phosphorylated receptor displayed an enrichment for DNA motifs that were distinct from that of total ERa in proliferating cells, suggesting that the phosphorylation directly alters the DNAbinding capacities of specificity of the receptor. The top three enriched motifs underlying ERaS305-P-binding events were AHR, EGR3 and E2F1. These transcription factors are not surprising hits, as each of these has previously been described to have essential roles in ERa biology. EGR3 has been described to be involved in ERa signaling 44 and ERa-mediated invasion, and its expression correlates with poor outcome. 45 E2F1 on the other hand was found to be an ERa target that mediates TAM resistance 41 and estradiol-stimulated cell proliferation. 46 AHR crosstalks with ERa 43 and modulates ERa-mediated gene regulation.
47,48
The crystal structure data of the full length RXR:PPARg heterodimer shows an alignment of the hinge region of PPARg along the DNA. 49 This may also occur with the hinge domain of ERa, thereby determining the DNA motif specificity of the receptor. Any modifications in the hinge domain (including S305 phosphorylation) may, as a consequence, alter the DNA-binding preferences of the receptor. The altered positioning of ERa when phosphorylated at S305 is surprising, but unlikely to be dictated by this post-translational modification alone. Most likely, the S305-P modification attracts different co-factors that in assembly alter the chromosome-binding preferences of the receptor. Such effects can be mediated further by phosphorylation of CARM1 26 or AIB1, 25 but may also be dictated by other factors. ERa-binding events are not rigid, but can differ between cell lines 50 and the chromatin-binding pattern can be manipulated by growth factor stimulation. 28 To our knowledge, this is the first report describing the direct effect of phosphorylation on the chromatin-binding landscape of ERa. The distinct and unique patterns as observed here suggest that phosphorylation events on the receptor not only dictate the transcriptional readout, 17 the transcript repertoire 22 and cofactor preferences, 21 but also determine to what DNA regions the receptor is able to bind. This yields a complicated view on transcriptional regulation by ERa. As this protein can be modified at different locations by different kinases, different chromatin deposition and thus transcription may be the result. Depending on the activated signaling pathway, a different DNA-binding preference of ERa after estrogen activation or TAM exposure may be the result.
Many more ERa-/chromatin-binding events exist as compared with estradiol-responsive genes. 37, 51, 52 Apparently, the same holds true for ERaS305P-binding events. Yet, a clear enrichment of the phosphorylated ERa was found at gene promoters. About 25% of the 3327 binding events was found at a promoter, implying about 830 peaks. Out of the 100 differentially expressed genes that were shared between the MCF7 and MDA-MB-134 cell lines, 26 had at least one proximal ERaS305-P-binding event, presenting a statistical enrichment over genomic background (Fisher's exact test; P ¼ 0.024).
Although we find an enrichment at promoters, not all ERaS305-P bound promoters result in the expression of the corresponding gene in our microarray analyses. This could arise because of the temporal nature of the expression array experiments, suggesting different time points may be needed to pick up differential expression of all the genes. Nevertheless, our data show that an enrichment of ERaS305-P at promoter sites correlates with expression of the corresponding genes.
We show here for the S305 modification that distinct transcriptional pathways are generated that can explain cell growth of breast cancer cells in response to TAM. Ingenuity pathway analysis illustrated that only limited overlap exists between E2 and ERaS305 associated pathways, even though a high-scoring 'cell proliferation' network was shared between the two conditions (Supplementary Figure S5 and Table S5 ). What the physiological effects from all non-overlapping pathways would be still needs to be deciphered, and the additive value of any of these networks in TAM resistance cannot be ruled out. The ERaS305-P distinct gene set has led to the development of a classifier that allows prediction of patient's responses to TAM treatment. Further analyses show that the MYC pathway in particular can be activated, which may explain the more aggressive behavior of such tumors.
Our data illustrate that one single post-translational modification can have a major impact on the chromatin-interaction patterns and transcriptome of the ERa. ERaS305 phosphorylation greatly affects its DNA-binding sites, giving rise to distinct responsive gene signature that includes MYC and its related genes. MYC overexpression overcomes TAM action on cell proliferation and hence, a PKA-induced elevation of MYC would induce resistance to TAM. Myc is a well-described ERa-estradiolresponsive gene, 40 not solely an ERaS305P dependent gene. However, here we postulate that Myc activation is a means of PKAinduced TAM-resistance, where the typical E2-dependent Myc gene is now activated by a PKA-induced ERaS305P. A link between TAM resistance and Myc has been previously described, 40 for which we now present one mechanism by which this can occur.
The plasticity in the chromatin-binding patterns of ERa as induced by PKA-activation has significant downstream effects that may lie at the very basis of TAM-resistance of breast cancer patients. The genes differentially targeted and transcribed by S305-phosphorylated ERa indeed act as a biologically relevant and understandable classifier for breast cancer patient responses to TAM treatment.
MATERIALS AND METHODS
Cell culture MCF7 and MDA-MB-134 cells were cultured in DMEM supplemented with 8% FBS and antibiotics (penicillin, streptavidin). To deprive cells of hormones, they were cultured in phenol-red free DMEM with 5% charcoal-treated serum and antibiotics. Cells were stimulated with 10 
Microarray experiments
Cells were harvested and homogenized in trizol (Invitrogen, Grand Island, NY, USA). RNA was isolated and hybridized on IlluminaWG-6 expression BeadChip (Illumina, San Diego, CA, USA; MDA-MB-134) and Human HT-12 v4 Expression BeadChip (MCF7, performed in triplicate). For data extraction, we used no background correction, applied variance stabilizing transformation and robust spline normalization. Data were log-transformed, ratios of the absolute values were calculated. For the RI-plots, the log-ratio was plotted over the intensity, calculated from the absolute intensities as follows: R ¼ log (PKA-activated/ control) and I ¼ log (PKA-activated x control). P-values absolute-value ratios were calculated with a two-tailed paired t-test. Hits were selected on Po0.05 with a ratio threshold of 1.5 Â .
Bioinformatics patient data set
We extracted the ERa positive, TAM-treated tumors from two published patient data sets. 33, 32 All the expression data were retrieved for the 100 hits in the classifier. The average expression of all the tested genes was calculated, ranked and divided in two groups. Patients who were stratified in two groups are as follows: (1) upregulated genes in the top 50% and the downregulated genes in the bottom 50%. (2) upregulated genes in the bottom 50% and the downregulated genes in the top 50%. Kaplan-Meier plots were generated using Prism 5 (Graphpad software, La Jolla, CA, USA). P-values were calculated using a log-ranked Gehan-Breslow-Wilcoxon method.
qPCR Cells were harvested and homogenized in trizol. RNA isolation for qPCR was performed by a phenol-chloroform extraction. cDNA was made with a Superscript III RT kit (Invitrogen) using the manufacturer's protocols. qPCR for cDNA and for ChIP-DNA was performed with SYBR Green (Applied Biosystems, Carlsbad, CA, USA) on a Chromo4 RT detector (Bio-Rad, Hercules, CA, USA) using standard protocols. Primers (Invitrogen) were designed with primer3 v0.4.0 and are shown in Supplementary Table S6 .
ChIP-seq
ChIP experiments were performed as described previously. 53 The antibody used was anti-ERaS305-P (Millipore/Upstate). ChIP-DNA was amplified as described. 35 Sequences were generated by the Illumina GAIIx genome analyzer (using 36-bp reads), processed by the Illumina analysis pipeline version 1.6.1, and aligned to the Human Reference Genome (assembly hg18, NCBI Build36.1, March 2008) using BWA version 0.5.5. Reads were filtered by removing those with a BWA alignment quality score o15. A corresponding set of input sequence reads of similar size was obtained by random sampling from the full set of input sequence reads. Enriched regions of the genome were identified by comparing the ChIP samples to input samples using the MACS peak caller 54 version 1.3.7.1 and SICER version 0.0.1, 55 where only the peaks shared by both methods were considered.
MYC overexpression and cell proliferation assay 
